aTyr Pharma (NASDAQ:ATYR) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

aTyr Pharma (NASDAQ:ATYR) had its price objective boosted by Wells Fargo & Company from $1.00 to $4.00 in a report released on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 37.01% from the company’s current price.

ATYR has been the topic of several other research reports. Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Wall Street Zen raised aTyr Pharma to a “hold” rating in a research note on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.00.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock opened at $6.35 on Friday. The company has a market capitalization of $15.56 million, a P/E ratio of -0.29 and a beta of 1.04. aTyr Pharma has a 1 year low of $4.07 and a 1 year high of $44.40. The company’s fifty day moving average is $11.68 and its two-hundred day moving average is $23.59.

aTyr Pharma (NASDAQ:ATYR) last announced its earnings results on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). The firm had revenue of $235.23 million for the quarter, compared to analyst estimates of $2.50 million. As a group, equities analysts expect that aTyr Pharma will post -17.80 earnings per share for the current year.

Institutional Trading of aTyr Pharma

An institutional investor recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC bought a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,522 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.